ABVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABVX is a good buy right now for a beginner long-term investor with $50,000-$100,000 available, and I would rate it as a buy. The stock has strong bullish technical momentum, supportive analyst coverage, and meaningful clinical upside from its lead drug program. The lack of a buy signal from AI Stock Picker or SwingMax means this is not an aggressive signal-driven entry, but the broader setup remains favorable. Given the investor wants long-term exposure and is impatient, this is still an acceptable entry rather than a stock to wait on.
The technical picture is bullish. MACD histogram is positive and expanding, which supports upward momentum. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, indicating a strong trend structure. RSI_6 at 73.052 is elevated, showing the stock is extended in the near term, but it does not overturn the broader trend. Price is trading above the pivot at 122.147 and below first resistance at 131.753, so the stock is holding near breakout territory. Overall trend: bullish with short-term overextension, but still constructive.
["Jefferies initiated coverage with a Buy rating and $160 price target, calling obefazimod differentiated and maintenance data fairly de-risked.", "Barclays raised its price target to $148 and kept Overweight, citing a clean DSMB review and late Q2 readout.", "Oddo BHF raised its target to EUR 120 and kept Outperform, highlighting Crohn's disease as a large opportunity.", "Q1 2026 clinical data showed 68% remission in ulcerative colitis in Study 108, supporting the drug's potential.", "Cash position of \u20ac491.6 million provides runway into Q4 2027, reducing near-term financing pressure.", "Positive biotech sector backdrop with critical Phase 2 milestones approaching across the space."]
["No AI Stock Picker signal today and no recent SwingMax entry signal.", "RSI is elevated, suggesting the stock may be near-term stretched.", "Q1 2026 net loss of \u20ac52.4 million and R&D expenses of \u20ac49.5 million reflect ongoing cash burn.", "Congress trading shows 1 sale and 0 purchases in the last 90 days, signaling cautious sentiment.", "Hedge funds and insiders are neutral, with no significant buying trend.", "Stock trend estimate suggests only modest near-term performance after a possible short-term pullback."]
Latest reported quarter: Q1 2026. Abivax reported a net loss of €52.4 million, driven by increased R&D spending of €49.5 million. On the positive side, the company held €491.6 million in cash as of March 31, 2026, giving it a projected runway into Q4 2027. This is a solid liquidity position for a development-stage biotech, and the key financial trend is continued heavy investment in R&D rather than revenue-driven growth.
Analyst sentiment is clearly positive and improving. Jefferies initiated at Buy with a $160 target, Barclays raised its target to $148 and kept Overweight, and Oddo BHF lifted its target to EUR 120 while maintaining Outperform. The wall street pros are constructive because they see obefazimod as differentiated and the maintenance readout as de-risked, with Crohn's disease as an added upside opportunity. The main con view is that the company is still pre-commercial, loss-making, and dependent on clinical execution, so valuation is tied heavily to trial success.
